The popularity of Viagra initially sparked a surge for major pharmaceutical companies, but recent shifts present a murky scenario for shareholders. Generic alternatives are eating into profits, and ongoing legal battles add further difficulty to the equation. While some companies may still see gains from complementary offerings, the overall tren… Read More